Figure 6.
Subgroup analysis to estimate the benefits of PFS from adjuvant CIT. CIT significantly prolonged the PFS of EOC patients with residual tumors of no less than 1 cm. Patients with residual tumor ≥ 1 cm (A, n = 95) or residual tumor < 1 cm (B, n = 403) were divided and were analyzed. The PFS rate was evaluated by the Kaplan–Meier method and compared by the stratified log-rank test.